Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report

Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report
复制标题

DOI:
10.1007/s11282-018-0319-y
复制
发表时间:
2019-01-01
期刊:
影响因子:
2.2
通讯作者:
Tohnai, Iwai
Tohnai, Iwai
中科院分区:
医学4区
文献类型:
--
作者:
Sakuma, Kaname;Koizumi, Toshiyuki;Tohnai, Iwai

文献摘要

被引文献

相似文献

我们在此报告一例63岁男性口腔黏膜鳞状细胞癌合并N3颈部淋巴结转移的病例。患者接受了联合治疗,包括放疗(2Gy/天,总剂量70Gy),经颞浅动脉超选择性动脉化疗(多西他赛,总剂量70mg/m(2),顺铂,总剂量175mg/m(2)),西妥昔单抗(初始剂量400mg/m(2),随后每周剂量250mg/m(2)静脉注射),以及四个疗程的颈淋巴转移热疗。患者对治疗反应良好,原发肿瘤完全缓解。根治性颈部清扫和重建手术,包括切除覆盖的皮肤。N3和所有其他颈部淋巴结转移达到病理完全缓解。患者在治疗后3年内无复发迹象。基于本病例的研究结果,逆行超选择性动脉内放化疗联合热疗和西妥昔单抗似乎是治疗口腔癌N3颈部淋巴结转移患者的一种有希望的方式。
We herein report a case of squamous cell carcinoma of the buccal mucosa with N3 cervical lymph node metastasis in a 63-year-old man. The patient was treated with combination therapy comprising radiotherapy (2Gy/day, total of 70Gy), superselective intra-arterial chemotherapy via a superficial temporal artery (docetaxel, total of 70mg/m(2) and cisplatin, total of 175mg/m(2)), cetuximab (initial dose of 400mg/m(2) with subsequent weekly doses of 250mg/m(2) intravenously), and four sessions of hyperthermia for cervical lymph node metastases. The patient responded well to the therapy, with a complete response of the primary tumor. Radical neck dissection was performed with reconstructive surgery, including resection of the overlying skin. A pathologic complete response was achieved for the N3 and all other cervical lymph node metastases. The patient showed no evidence of recurrence in the 3years following treatment. Based on the findings in the present case, the use of retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab seems to be a promising modality for patients with N3 cervical lymph node metastasis of oral cancer.